Get the Stockscreener App
4.11
5.67%
0.05
Camp 4 Therapeutics Corp stock is traded at $4.11, with a volume of 28,234.
It is up +5.67% in the last 24 hours and down -7.74% over the past month.
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
See More
Previous Close:
$4.06
Open:
$4.01
24h Volume:
28,234
Relative Volume:
0.16
Market Cap:
$219.39M
Revenue:
$3.50M
Net Income/Loss:
$-80.40M
P/E Ratio:
-1.5985
EPS:
-2.5711
Net Cash Flow:
$-29.83M
1W Performance:
+2.88%
1M Performance:
-7.74%
6M Performance:
+0.94%
1Y Performance:
+95.89%
1-Day Range:
$4.00
$4.35
1-Week Range:
$3.80
$4.37
52-Week Range:
$1.305
$7.75
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Name
Camp 4 Therapeutics Corp
Sector
Industry
Phone
617-651-8867
Address
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.225 | 210.82M | 3.50M | -80.40M | -29.83M | -2.5711 |
VRTX
Vertex Pharmaceuticals Inc
|
426.44 | 108.54B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
711.31 | 75.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.00 | 50.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.95 | 40.45B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.66 | 32.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Rodman & Renshaw | Buy |
| Oct-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-16-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-27-25 | Initiated | Wedbush | Outperform |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | William Blair | Outperform |
| Aug-16-22 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-22-21 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-24-21 | Reiterated | Craig Hallum | Buy |
| Jun-25-21 | Reiterated | Craig Hallum | Buy |
| Dec-18-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-17-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-05-20 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Jun-28-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-01-19 | Reiterated | Craig Hallum | Buy |
| Mar-25-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-25-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-18 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-14-18 | Reiterated | B. Riley FBR | Buy |
| Dec-11-18 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Dec-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| Nov-27-18 | Initiated | Goldman | Neutral |
| Oct-15-18 | Initiated | Jefferies | Hold |
| Sep-28-18 | Reiterated | Craig Hallum | Hold |
| Apr-27-18 | Reiterated | Craig Hallum | Hold |
| Mar-08-18 | Downgrade | Craig Hallum | Buy → Hold |
| Feb-16-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
View All
Camp 4 Therapeutics Corp Stock (CAMP) Latest News
Camp4 Therapeutics Corp engages with SYNGAP1 families to inform regRNA therapeutic progress - Traders Union
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation - The Manila Times
CAMP4 maps thousands of new RNAs for gene-boosting drugs - Stock Titan
Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN
CAMP4 (CAMP) details director votes, auditor ratification and equity plan - Stock Titan
[ARS] Camp4 Therapeutics Corp SEC Filing - Stock Titan
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March - MarketBeat
Three new CAMP4 hires get stock options at $4.59 a share - Stock Titan
Camp4 Therapeutics Corp boosts team engagement with employee event on the slopes - Traders Union
CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw - MarketBeat
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating By Investing.com - Investing.com Australia
Rodman & Renshaw initiates CAMP4 Therapeutics stock with buy rating - Investing.com
CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H - MarketBeat
Life sciences leaders unite at Camp4 Therapeutics Corp-backed event supporting health equity - Traders Union
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CAMP Technical Analysis | Trend, Signals & Chart Patterns | CAMP4 THERAPEUTICS CORP (NASDAQ:CAMP) - ChartMill
Camp4 Therapeutics Corp advances creative strategies in complex drug discovery partnerships - Traders Union
Is CAMP4 (CAMP) Stock Good for Beginners | Price at $4.72, Up 5.59%Aggressive Growth Stocks - Newser
Camp4 Therapeutics (CAMP) grants 170,000 stock options to Chief Scientific Officer - Stock Titan
Camp4 Therapeutics (CAMP) CMO receives 215,000 stock options grant - Stock Titan
Camp4 Therapeutics (CAMP) CFO receives 215,000 stock options grant - Stock Titan
Camp4 Therapeutics Corp (CAMP) CEO granted 580,000 stock options at $4.46 - Stock Titan
Camp4 Therapeutics (CAMP) director awarded 56,000 stock options at $4.46 strike - Stock Titan
Camp4 Therapeutics (CAMP) director Michael MacLean files initial Form 3 - Stock Titan
Amazon To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Sahm
CAMP Stock Analysis: CAMP4 Therapeutics biotech review at 4.47 small daily gain - Newser
Leerink raises CAMP4 Therapeutics price target on CMP-002 progress By Investing.com - Investing.com South Africa
Leerink raises CAMP4 Therapeutics price target on CMP-002 progress - Investing.com
CAMP PE Ratio & Valuation, Is CAMP Overvalued - Intellectia AI
Aug Swings: Should value investors consider Camp4 Therapeutics Corporation2026 Earnings Surprises & Daily Entry Point Alerts - baoquankhu1.vn
CAMP4 Therapeutics Adds Veteran CFO MacLean to Board - TipRanks
CAMP4 Therapeutics Corporation Files Form 8-K for NASDAQ Listing – Company Details and Key Information (March 2026) - Minichart
CAMP4 Appoints Michael MacLean to its Board of Directors - Bitget
Camp4 Therapeutics appoints Michael MacLean to board and expands director compensation - Investing.com Australia
Camp4 Therapeutics appoints Michael MacLean to board and expands director compensation By Investing.com - Investing.com South Africa
CAMP4 Therapeutics appoints Michael MacLean to board of directors - investing.com
CAMP4 Therapeutics appoints Michael MacLean to board of directors By Investing.com - Investing.com UK
Camp4 Therapeutics appoints Michael MacLean as director, joins Audit and Compensation Committees - TradingView
Camp4 Therapeutics Corp adds veteran leader to accelerate regRNA-based therapy clinical push - Traders Union
Biotech CAMP4 taps veteran CFO as it pushes SYNGAP1 drug to trial - Stock Titan
New CAMP4 (NASDAQ: CAMP) director MacLean joins, receives option grant - Stock Titan
If You Invested $1,000 in Camp4 Therapeutics Corp. (CAMP) - Stock Titan
Camp4 Therapeutics (CAMP) holder Enavate cuts stake to 4.8% of shares - Stock Titan
EVTL Technical Analysis & Price Forecast - Intellectia AI
Camp4 Therapeutics: Strong Cash Runway As CMP-002 Moves Toward Human Trials (NASDAQ:CAMP) - Seeking Alpha
CAMP4 to Participate in Upcoming Investor Conferences - The Manila Times
Biotech firm CAMP4 lines up 3 healthcare investor events - Stock Titan
Cantor Fitzgerald reiterates Overweight on CAMP4 stock, $7 target - Investing.com India
Cantor Fitzgerald reiterates Overweight on CAMP4 stock, $7 target By Investing.com - Investing.com Australia
Camp 4 Therapeutics Corp Stock (CAMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Camp 4 Therapeutics Corp Stock (CAMP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Polaris Management Co. VII, L. | 10% Owner |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Nashat Amir | Director |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Maricich Yuri | Chief Medical Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
6,060 |
| Gold Kelly | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
67,877 |
| Mandel-Brehm Josh | Chief Executive Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
278,417 |
| Young Richard A | Director |
Sep 11 '25 |
Buy |
1.65 |
15,151 |
24,999 |
170,010 |
5.78%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):